Biohaven continues push for oral migraine med Nurtec amid new portfolio line up
Biohaven is spending to move the oral migraine drug market — and it seems to be working. The biopharma reported $463 million in Nurtec sales for 2021, with $190 million of that in the fourth quarter alone, it reported during an earnings call Friday.
Driving that growth? SG&A expenses of $189 million in the fourth quarter, an increase of 66% over the same period in the previous year. SG&A or selling, general and administrative costs include everyday operating expenses that include things salaries and marketing and advertising expenses.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.